The next HPV vaccine approved in the United States, called Cervarix, is a bivalent vaccine that protects against HPV types 16 ...

One dose of a human papillomavirus (HPV) vaccine was noninferior to two doses in preventing infection, data from a randomized trial showed. In the ESCUDDO trial, which involved more than 20,000 ...

covering more types of HPV. Until 2012, the vaccine in use was the bivalent Cervarix, targeting HPV 16 and 18. Then the quadrivalent Gardasil was administered until 2023, when the nonavalent ...

The HPV bivalent vaccine (Cervarix) will only protect against HPV 16 and 18. The HPV quadrivalent vaccine (Gardasil) will protect against HPV types 6, 11, 16, and 18. The HPV 9-valent vaccine ...

CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials for its innovative bivalent HPV mRNA vaccine, SYS6026.

In the ESCUDDO trial, which involved more than 20,000 girls ages 12 to 16, one dose of both the bivalent Cervarix and 9-valent Gardasil 9 HPV vaccines provided similar protection to two doses ...